New shot could help control rare lung disease
NCT ID NCT07601295
First seen May 29, 2026 · Last updated Jun 22, 2026 · Updated 4 times
Summary
This phase 2 trial tests whether adding tiprelestat (elafin) to standard care improves outcomes for people with pulmonary arterial hypertension (PAH), a serious lung condition. About 90 adults will receive either a daily injection of tiprelestat or a placebo for 168 days. The main goal is to see if the drug lowers pulmonary vascular resistance, a key measure of disease severity.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION (PAH) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brown University/Rhode Island Hospital
Providence, Rhode Island, 02904, United States
-
Duke University
Durham, North Carolina, 27710, United States
-
Harvard University / Brigham and Women's Hospital
Boston, Massachusetts, 02138, United States
-
Stanford University
Stanford, California, 94305, United States
-
The University of Arizona / Banner University Medical Center
Tucson, Arizona, 85719, United States
-
University of California, San Francisco
San Francisco, California, 94143, United States
-
University of Colorado (UCD) Anschutz
Aurora, Colorado, 80045, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
University of Texas Southwestern
Dallas, Texas, 75390, United States
-
University of Washington
Seattle, Washington, 98195, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tiprelestat (also known as elafin)
What this could lead to
If it works, this could point toward a new add-on treatment to better control pulmonary arterial hypertension and improve heart function.
What could go wrong
This is an early phase 2 trial with only 90 participants, so results may not apply to everyone. The drug is injected daily, which may be inconvenient, and side effects are still being studied.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.